$DCOYAug 3, 2026, 1:00 PMAI processed
Decoy (DCOY) expands IP to cover D‐MAVs, manufacturing and IMP3ACT design platform
AI Summary
Decoy Therapeutics (NASDAQ: DCOY) expanded its intellectual property portfolio to seven patent families with one granted U.S. patent and 19 pending applications across seven jurisdictions, covering antiviral peptide conjugates, manufacturing methods, formulations and the IMP3ACT design platform. The granted U.S. patent (No. 12,226,474) claims antiviral peptide conjugates with D‐amino acid viral spike sequences, and a June 2026 filing covers the platform's design methods—strengthening proprietary protection for its Designable Multi‐Antivirals while most applications remain pending.
Positives
- Portfolio now comprises seven patent families with one granted U.S. patent and 19 pending applications across US, Australia, Canada, China, Europe, Japan and New Zealand
- Coverage explicitly includes compositions of matter, automated manufacturing methods, formulations and the IMP³ACT design platform
- All patents and applications are solely owned by Decoy
Negatives
- Majority of filings are pending and may not be granted
- Patent protection does not address clinical, regulatory or financing risks for product development
- Announcement contains no new clinical or IND milestone information